In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amir Belson: Stealth Medtech Entrepreneur

Executive Summary

Amir Belson is among the most prolific device entrepreneurs in the industry today, having launched a dozen companies in the past 12 years. Not as well-known as other physician-inventors, he combines an aggressive IP strategy with an innovative approach to early-stage financing to launch companies in a variety of clinical spaces.

You may also be interested in...



Hypothermia Device Companies Continue To Wage Cold War

For therapeutic hypothermia device companies, the clinical trials that came before have been inconclusive, but they have provided insights to incorporate into the development of next-generation technologies. START-UP interviews two hypothermia device companies with novel approaches: Thermocure and ThermopeutiX.

Avinger: Finally, Seeing Through Total Occlusions, But Will Clinical Value Generate Economic Return?

Noted physician/entrepreneur John Simpson is back. His latest company, Avinger, has finally achieved his long-sought goal: combining imaging and therapeutics in catheter technology for crossing CTOs. Will clinical innovation be enough to reward Avinger in an increasingly economically focused medtech world?

VasoStitch Inc.

Delivering valve devices to a structurally damaged heart through the femoral artery can be a tricky proposition. Cardiologists normally gain access through a large incision and employ balloons to increase the diameter of the aperture. Problems can arise when trying to close the hole at the end of the procedure. New technology from VasoStitch Inc. allows for simpler and safer access and closure of catheter-based interventions for minimally invasive valve replacement and repair. The start-up’s two devices, yet to be branded, are for accessing the heart through the femoral artery (transfemorally) and the chest wall (transapically), respectively

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel